MedPath

Zagotenemab

Generic Name
Zagotenemab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
2019133-28-7
Unique Ingredient Identifier
AY6V5E2GNX
Background

Zagotenemab is under investigation in clinical trial NCT03518073 (A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease).

Associated Conditions
-
Associated Therapies
-
dovepress.com
·

Prevention and treatment strategies for Alzheimer's disease: Focusing

Alzheimer’s disease (AD) involves progressive neurodegeneration, characterized by cognitive decline and accumulation of β-amyloid protein (Aβ) and neurofibrillary tangles (NFTs). Neuroinflammation, driven by microglia and astrocytes, plays a crucial role in AD pathogenesis. Microglia phagocytose Aβ but can exacerbate disease if overactivated. Astrocytes, though protective, can contribute to neuroinflammation and Aβ production when reactive. Current treatments, including monoclonal antibodies targeting Aβ, show promise but do not reverse disease. Future research aims to mitigate neuroinflammation and enhance protective microglia-astrocyte interactions for potential AD therapies.
© Copyright 2025. All Rights Reserved by MedPath